Skip to main content
. 2022 Dec 10;12(12):e1093. doi: 10.1002/ctm2.1093

TABLE 3.

Human clinical application using the stromal vascular fraction (SVF) with outcomes

Trial Title Diseases SVF concentration and administration route
31327120 Human intracerebroventricular (ICV) injection of autologous, non‐engineered, adipose‐derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3‐year Phase I study of 113 injections in 31 patients
  • ‐

    Amyotrophic lateral sclerosis (ALS), n = 6

  • ‐

    Dementias (AD), n = 10

  • ‐

    Parkinson's‐like syndromes (PD+) (including multiple system atrophy and progressive supranuclear palsy, n = 6

  • ‐

    Traumatic brain injury (TBI), n = 1

  • ‐

    Multiple sclerosis—progressive form (MS‐P), n = 6

  • ‐

    Stroke, n = 1

  • ‐

    Spinal cord injury (SCI), n = 1
  • ‐

    Frontal horn of lateral ventricle via Ommaya reservoir (n = 24)

  • ‐

    shunt (n = 7)

  • ‐

    4.05 × 105–6.2 × 107 cells/cc

  • ‐

    3.5–20 cc injected (median 4 cc)
33222965 Sustained clinical improvement of Parkinson's disease in two patients with facially transplanted adipose‐derived stromal vascular fraction cells
  • ‐

    Parkinson's

 Facial injections using 21 g needle
  • ‐

    Patient 1: 73.8 × 106 cells suspended in 100 cc of Hartmann solution, distributed equally in 3 different locations

  • ‐

    Patient 2: 68 × 106 cells suspended in 100 cc of Hartmann solution, distributed equally between 2 sites

Note: Review methods: PubMed and clinicaltrial.gov search – input words: SVF, stromal vascular fraction, neurodegeneration.